NASDAQ:TVTX Travere Therapeutics (TVTX) Stock Forecast, Price & News $8.66 +0.13 (+1.52%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$8.55▼$9.0250-Day Range$7.64▼$17.2552-Week Range$7.00▼$26.55Volume2.11 million shsAverage Volume1.44 million shsMarket Capitalization$649.59 millionP/E RatioN/ADividend YieldN/APrice Target$22.77 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Travere Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside162.9% Upside$22.77 Price TargetShort InterestBearish12.05% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.20Based on 28 Articles This WeekInsider TradingSelling Shares$98,954 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.10) to ($4.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.02 out of 5 starsMedical Sector613th out of 976 stocksPharmaceutical Preparations Industry292nd out of 456 stocks 4.3 Analyst's Opinion Consensus RatingTravere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 10 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.77, Travere Therapeutics has a forecasted upside of 162.9% from its current price of $8.66.Amount of Analyst CoverageTravere Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.05% of the outstanding shares of Travere Therapeutics have been sold short.Short Interest Ratio / Days to CoverTravere Therapeutics has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Travere Therapeutics has recently increased by 5.73%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTravere Therapeutics does not currently pay a dividend.Dividend GrowthTravere Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TVTX. Previous Next 2.1 News and Social Media Coverage News SentimentTravere Therapeutics has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 28 news articles for Travere Therapeutics this week, compared to 3 articles on an average week.Search Interest11 people have searched for TVTX on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.MarketBeat Follows2 people have added Travere Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $98,954.00 in company stock.Percentage Held by InsidersOnly 4.71% of the stock of Travere Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Travere Therapeutics are expected to grow in the coming year, from ($5.10) to ($4.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Travere Therapeutics is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Travere Therapeutics is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTravere Therapeutics has a P/B Ratio of 12.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Travere Therapeutics (NASDAQ:TVTX) StockTravere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Read More TVTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TVTX Stock News HeadlinesSeptember 26, 2023 | markets.businessinsider.comStifel Nicolaus Sticks to Their Hold Rating for Travere Therapeutics (TVTX)September 26, 2023 | finance.yahoo.comTravere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)September 27, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 24, 2023 | msn.comWilliam Blair Downgrades Travere Therapeutics (TVTX)September 24, 2023 | americanbankingnews.comWells Fargo & Company Downgrades Travere Therapeutics (NASDAQ:TVTX) to Equal WeightSeptember 24, 2023 | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) PT Lowered to $18.00September 24, 2023 | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) PT Lowered to $12.00September 24, 2023 | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) PT Lowered to $14.00September 27, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.September 24, 2023 | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) Price Target Cut to $18.00September 24, 2023 | americanbankingnews.comBank of America Lowers Travere Therapeutics (NASDAQ:TVTX) Price Target to $27.00September 23, 2023 | msn.comBarclays Maintains Travere Therapeutics (TVTX) Overweight RecommendationSeptember 23, 2023 | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) Downgraded by William BlairSeptember 23, 2023 | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) Shares Gap Down After Analyst DowngradeSeptember 22, 2023 | msn.comGuggenheim Maintains Travere Therapeutics (TVTX) Buy RecommendationSeptember 22, 2023 | msn.comWells Fargo Downgrades Travere Therapeutics (TVTX)September 22, 2023 | seekingalpha.comTravere Therapeutics: Tanking On Confirmatory Trial Failure For Kidney Therapy - Is There Hope?September 22, 2023 | seekingalpha.comPROTECT Study Clouds Travere Therapeutics' Outlook (Rating Downgrade)September 22, 2023 | americanbankingnews.comInvestors Purchase Large Volume of Put Options on Travere Therapeutics (NASDAQ:TVTX)September 21, 2023 | msn.comTravere Therapeutics shares plunge as kidney-disease treatment has mixed results in trialSeptember 21, 2023 | finance.yahoo.comTravere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, IrbesartanSeptember 20, 2023 | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) Given Outperform Rating at Evercore ISISeptember 19, 2023 | markets.businessinsider.comEvercore ISI Group Maintains Outperform Rating for Travere Therapeutics: Here's What You Need To KnowSeptember 7, 2023 | nasdaq.comEvercore ISI Group Reiterates Travere Therapeutics (TVTX) Outperform RecommendationSeptember 5, 2023 | finance.yahoo.comTravere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum PharmaceuticalsSeptember 5, 2023 | finance.yahoo.comMirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere TherapeuticsAugust 31, 2023 | finance.yahoo.comTravere Therapeutics to Present at the 2023 Wells Fargo Healthcare ConferenceSee More Headlines Receive TVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TVTX Company Calendar Last Earnings8/03/2023Today9/27/2023Next Earnings (Estimated)10/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TVTX CUSIPN/A CIK1438533 Webwww.retrophin.com Phone(888) 969-7879Fax302-645-1280Employees462Year FoundedN/APrice Target and Rating Average Stock Price Forecast$22.77 High Stock Price Forecast$38.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+163.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($4.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-278,480,000.00 Net Margins-136.00% Pretax Margin-135.85% Return on Equity-273.80% Return on Assets-41.78% Debt Debt-to-Equity Ratio3.23 Current Ratio3.99 Quick Ratio3.86 Sales & Book Value Annual Sales$212.02 million Price / Sales3.06 Cash FlowN/A Price / Cash FlowN/A Book Value$0.67 per share Price / Book12.90Miscellaneous Outstanding Shares75,010,000Free Float71,478,000Market Cap$648.09 million OptionableOptionable Beta0.42 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Eric M. Dube Ph.D. (Age 50)Pres, CEO & Director Comp: $1.35MMr. Christopher Cline C.F.A. (Age 38)CFA, Chief Financial Officer Comp: $634.36kDr. William E. Rote Ph.D. (Age 60)Sr. VP and Head of R&D Comp: $733.25kMr. Peter Heerma (Age 52)Chief Commercial Officer Comp: $705.62kDr. Jula Inrig M.D. (Age 48)Chief Medical Officer Comp: $815.93kMs. Sandra Calvin (Age 57)SVP, Corp. Controller & Chief Accounting Officer Ms. Elizabeth E. Reed (Age 52)Sr. VP, Gen. Counsel & Corp. Sec. Ms. Charlotte SmithSr. VP of Public AffairsMr. Casey LoganSr. VP of Corp. & Bus. Devel.Ms. Angela GiannantonioSr. VP of HRMore ExecutivesKey CompetitorsAvid BioservicesNASDAQ:CDMOKura OncologyNASDAQ:KURAPureTech HealthNASDAQ:PRTCBicycle TherapeuticsNASDAQ:BCYCCentessa PharmaceuticalsNASDAQ:CNTAView All CompetitorsInsiders & InstitutionsEric M DubeSold 4,455 sharesTotal: $65,533.05 ($14.71/share)William E RoteSold 1,815 sharesTotal: $26,698.65 ($14.71/share)Christopher R ClineSold 457 sharesTotal: $6,722.47 ($14.71/share)Nuveen Asset Management LLCBought 563,124 shares on 8/16/2023Ownership: 1.188%Alliancebernstein L.P.Bought 11,300 shares on 8/15/2023Ownership: 0.094%View All Insider TransactionsView All Institutional Transactions TVTX Stock - Frequently Asked Questions Should I buy or sell Travere Therapeutics stock right now? 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last twelve months. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TVTX shares. View TVTX analyst ratings or view top-rated stocks. What is Travere Therapeutics' stock price forecast for 2023? 15 Wall Street research analysts have issued 12 month price objectives for Travere Therapeutics' stock. Their TVTX share price forecasts range from $8.00 to $38.00. On average, they predict the company's share price to reach $22.77 in the next year. This suggests a possible upside of 163.5% from the stock's current price. View analysts price targets for TVTX or view top-rated stocks among Wall Street analysts. How have TVTX shares performed in 2023? Travere Therapeutics' stock was trading at $21.03 at the start of the year. Since then, TVTX stock has decreased by 58.9% and is now trading at $8.64. View the best growth stocks for 2023 here. When is Travere Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023. View our TVTX earnings forecast. How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:TVTX) released its earnings results on Thursday, August, 3rd. The company reported ($1.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.03. The firm earned $59.70 million during the quarter, compared to analysts' expectations of $53.93 million. Travere Therapeutics had a negative trailing twelve-month return on equity of 273.80% and a negative net margin of 136.00%. What ETFs hold Travere Therapeutics' stock? ETFs with the largest weight of Travere Therapeutics (NASDAQ:TVTX) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI) and ALPS Medical Breakthroughs ETF (SBIO).Direxion Daily S&P Biotech Bull 3x Shares (LABU). What is Travere Therapeutics' stock symbol? Travere Therapeutics trades on the NASDAQ under the ticker symbol "TVTX." Who are Travere Therapeutics' major shareholders? Travere Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Deep Track Capital LP (9.83%), State Street Corp (7.64%), Renaissance Technologies LLC (2.07%), Kynam Capital Management LP (1.94%), Geode Capital Management LLC (1.86%) and Assenagon Asset Management S.A. (1.47%). Insiders that own company stock include Christopher R Cline, Elizabeth E Reed, Eric M Dube, Jula Inrig, Laura Clague, Noah L Rosenberg, Noah L Rosenberg, Peter Heerma, Sandra Calvin, Steve Aselage and William E Rote. View institutional ownership trends. How do I buy shares of Travere Therapeutics? Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Travere Therapeutics' stock price today? One share of TVTX stock can currently be purchased for approximately $8.64. How much money does Travere Therapeutics make? Travere Therapeutics (NASDAQ:TVTX) has a market capitalization of $648.09 million and generates $212.02 million in revenue each year. The company earns $-278,480,000.00 in net income (profit) each year or ($4.52) on an earnings per share basis. How many employees does Travere Therapeutics have? The company employs 462 workers across the globe. How can I contact Travere Therapeutics? Travere Therapeutics' mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The official website for the company is www.retrophin.com. The company can be reached via phone at (888) 969-7879, via email at ir@retrophin.com, or via fax at 302-645-1280. This page (NASDAQ:TVTX) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.